News

ADCT plans to initiate Phase I clinical trials in both NHL and ALL. ADCT-402 combines a humanized monoclonal antibody targeting CD19 with a pyrrolobenzodiazepine (PBD) warhead. In preclinical

Earlier this year, the company said it would delay its regulatory submission for basal insulin peglispro (BIL), the potential once-daily type 1 and type 2 diabetes treatment. The

The data supporting the application was generated in the four Phase 3 Astral clinical trials. Of the 1,035 patients treated with SOF/VEL for 12 weeks, 1,015 achieved the

The initial phase-one study will combine Amgen’s Blincyto (blinatumomab) with Merck’s Keytruda (pembrolizumab) to treat patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma.

Acorda executive director of device and program management Sean Plunkett said: "CVT-427 represents an innovative approach to acute treatment of migraines. Applying Acorda’s proprietary ARCUS technology, we have

"The current lack of effective therapies for high grade gliomas, such as glioblastoma and anaplastic astrocytoma, leaves doctors with few options for treating patients," said Tom Mikkelsen, M.D.,

The candidate is the fourth to be advanced from the company’s development pipeline in the last year, with the program reaching development stage under two years. Redx Pharma

Farletuzumab is a humanized monoclonal antibody (mAb) that binds to folate receptor alpha (FRA), a cell-surface protein highly expressed in ovarian carcinoma but largely absent from normal tissue.

The approval is conditional solely upon a minor change to the informed consent form that has already been submitted to the FDA. Full approval of the amendment is